Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
- 31 May 2004
- journal article
- case report
- Published by Elsevier in Leukemia Research
- Vol. 28, 71-73
- https://doi.org/10.1016/j.leukres.2003.10.017
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentBlood, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood, 2002